The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,314K data for 602K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

66 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation.EBI
Universidade de Lisboa
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.EBI
Lexicon Pharmaceuticals, Inc.
N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.EBI
National Health Research Institutes
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI
GlaxoSmithKline
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.EBI
AMRI
Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.EBI
CSIR-Indian Institute of Chemical Technology
Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes.EBI
Fudan University
Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes.EBI
Mitsubishi Tanabe Pharma Corporation
Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.EBI
National Taiwan University
N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.EBI
Mitsubishi Tanabe Pharma Corporation
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.EBI
Mitsubishi Tanabe Pharma Corporation
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-ylß-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).EBI
Kissei Pharmaceutical Company
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.EBI
Chugai Pharmaceutical Co. Ltd
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-ylß-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.EBI
Kissei Pharmaceutical Company
Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.EBI
National Health Research Institutes
C-Aryl 5a-carba-ß-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI
Chugai Pharmaceutical Co. Ltd
Discovery of novel N--D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.EBI
Taiwan National Health Research Institutes
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI
Lexicon Pharmaceuticals
Probing the conformation of the sugar transport inhibitor phlorizin by 2D-NMR, molecular dynamics studies, and pharmacophore analysis.EBI
Max-Planck-Institut f£r molekulare Physiologie
5a-Carba-ß-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI
Chugai Pharmaceutical Co. Ltd
C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI
Chinese Academy of Sciences
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.EBI
Amgen Inc
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.EBI
Pfizer Inc
Discovery of non-glucoside SGLT2 inhibitors.EBI
Amgen Inc
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.EBI
Mitsubishi Tanabe Pharma Corporation
ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.EBI
Chinese Academy of Sciences
Gneyulins A and B, stilbene trimers, and noidesols A and B, dihydroflavonol-C-glucosides, from the bark of Gnetum gnemonoides.EBI
Hoshi University
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.EBI
Taisho Pharmaceutical Co., Ltd
C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.EBI
Pfizer Inc
Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter.EBI
Hoshi University
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.EBI
Chinese Academy of Sciences
O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.EBI
Chinese Academy of Sciences
Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity.EBI
University Würzburg
Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens.EBI
Nippon Suisan Kaisha, Ltd
Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.EBI
Johnson & Johnson Pharmaceutical Research and Development LLC
Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.EBI
Johnson & Johnson Pharmaceutical Research and Development LLC
Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors.EBI
Johnson & Johnson Pharmaceutical Research and Development LLC
5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.EBI
Janssen Research & Development, L.L.C.
Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.EBI
Toho University
Anti-diabetic drugs recent approaches and advancements.EBI
Mizoram University
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.EBI
Chinese Academy of Sciences
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.EBI
Terns Pharmaceuticals
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.EBI
Jamia Hamdard
Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment.EBI
Taisho Pharmaceutical Co., Ltd.
Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes.EBI
Taisho Pharmaceutical Co., Ltd.
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.EBI
Janssen Research & Development, L.L.C.
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.EBI
Guangdong Pharmaceutical University
Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors.EBI
Janssen Research and Development, L.L.C.
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.EBI
National Health Research Institutes
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.EBI
Haisco Pharmaceuticals Group Co. Ltd.
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.BDB
Purdue University
Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.BDB
University of Kentucky
Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.BDB
Merck Sharp & Dohme Research Laboratories
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.BDB
Boehringer Ingelheim Pharmaceuticals Inc